



Interface Management of Pharmacotherapy
Promoting Hospital-Primary Care Collaboration for Rational Use of Medicines
Workshop and Site Visit

September 11–13, 2012
Stockholm, Sweden

Organized by

**Drug and Therapeutics Committee, Stockholm County Council, Stockholm,
Clinical Pharmacology at Karolinska Institutet and
Karolinska University Hospital in collaboration with
WHO Essential Medicines and Health Products**

Workshop and study visit to Stockholm

WHO realizes that new methods and models are needed across healthcare systems to improve the quality of drug therapy. Medicine selection and collaboration between primary and hospital care on Rational Use of Medicines (RUM) needs to be improved through shared recommendations of essential medicines. The aim is that pharmacotherapy should be rational for patients regardless of whether they are treated in ambulatory or in hospital care.

1. This 3-day study visit to Stockholm Healthcare Region will show a new model for improving quality of medicine use in the 2-million Stockholm metropolitan area. The *"Stockholm Model for Wise Use of Medicines"* is multifaceted with involvement of medical, clinical pharmacological, pharmaceutical and administrative staff. The focus is to improve *adherence to essential medicine recommendations* and strengthen the impact of the Drug and Therapeutics Committee using a "Wise List" of recommendations of essential medicines valid both for primary and hospital care provided for all healthcare providers in metropolitan Stockholm.
2. Healthcare providers and scientists around the globe are interested in evaluating what is known about models, experiences and effects of interface cooperation between primary and hospital care to improve the Rational Use of Medicines.
3. New initiatives for "Interface management of pharmacotherapy" will benefit from being shared at a "workshop"-like study visit.

Stockholm Model for Wise Use of Medicines

Stockholm County Council (Healthcare region) has developed and implemented a comprehensive way to improve quality of pharmacotherapy in the 2-million metropolitan capital of Sweden during the past 15 years, building on:

- The "Wise List" of recommendations of essential medicines jointly for primary and hospital care
- Medicine policy strategy
- Independent Drug and Therapeutics Committee with key roles for respected drug experts with a policy for "conflict of interest"
- Communication strategy with continuous medical education
- Methods and tools for follow-up of medicine use
- Systematic introduction of new expensive medicines
- Operative resources
- E-pharmacological support at "point of care"

Target group of participants

The target group for this study visit consists of 25 medical executives, advisors and researchers around the globe for this study visit in charge of enhancing the quality and efficiency of medical prescribing and medicine use in healthcare institutions, in particular at the interface between hospitals and primary care.

Target groups include:

- Senior medical and administrative managers and their advisors at hospitals, primary care boards, Ministries of Health, health authorities, health insurance agencies, in national medicine policy programmes and researchers in the field.
- Chief physicians and hospital pharmacists as well as pharmacotherapeutic, clinical pharmacological and pharmacist leaders of Drug and Therapeutics Committees.

Time for workshop and study visit

The workshop will last three full days September 11-13, 2012 including opportunities for extended discussions and in depth-studies with participating and organizing experts.

Application

Apply to wiselistmeetstockholm@sll.se. Please pay the course fee upon receipt of information on acceptance to the course. Fellowship may be provided for participants from developing and emerging countries.

Course fee

The course fee is €500 per person.

The fee includes reception, lunches, coffees and one dinner during the workshop. Each participant covers their own accommodation and travel costs. A list of recommended hotels can be provided.

International participants pay to account holder

Karolinska Institutet

Bank: SEB, KG2 Team Staten, S-106 40 Stockholm, Sweden

IBAN NO: SE15 5000 0000 0543 9102 8247

SWIFT: ESSESESS

Swedish participants pay to account holder

Karolinska Institutet

BG 5310-6654

Programme

Monday evening prior to start, September 10

Welcome reception in downtown Stockholm together with invited guests.
Hosts: Karolinska Institutet and Stockholm County Council

Day 1 – Tuesday, September 11

9.00 am-5.45 pm

Coordinating chair: Eva Andersén Karlsson

I: Welcome, aims and presentation of participants and organizers

Chair: Eva Andersén Karlsson

9.00-9.15 am

Welcome and aims of workshop and study visit

*Dr Richard Laing, WHO Geneva
Executive Head, Dr Catarina Andersson-Forsman,
Stockholm County Council Public Healthcare Services
Committee*

9.15-9.30 am

Details of study visit, presentation of organizers

*Associate professor Eva Andersén Karlsson, Chairperson,
Drug and Therapeutics Committee (DTC), Stockholm County
Council and
Professor Lars L Gustafsson, Karolinska Institutet and
Karolinska University Hospital, Stockholm*

9.30-9.50 am

Presentation of participants and review of expectations

All participants

II: Rational use of medicines: The challenge of interface collaboration between ambulatory and hospital care

Chair: Lars L Gustafsson

9.50-10.00 am

International perspective

*Richard Laing, WHO Geneva
(10 min presentation)*

10.00-10.35 am

European perspective

a. Scottish country-wide collaboration to integrate medicine therapy between primary and hospital care

*Professor Ken Paterson, University of Glasgow, Glasgow
(25 min presentation, 10 min comments)*

10.35-10.55 am

Tea/Coffee break

II: continuation

10.55-11.30 am **b. Catalanian country-wide collaboration to integrate medicine therapy between primary and hospital care**

Dr Eduardo Diogene,
Catalonian Healthcare Region, Barcelona
(25 min presentation, 10 min comments)

11.30-12.05 am **c. Interface management in Norway- status and initiatives at national and regional levels**

Senior advisor Dr Oyvind Melien,
Norwegian Directorate of Health, Oslo
Dr Jan-Henrik Lund, Chairman Drug and Therapeutics
Committee, Health Region South East, Oslo
(25 min presentation, 10 min comments)

12.05-12.15 am **Summing up, key conclusions module II**

12.15-1.15 pm **Lunch**

III: Stockholm Model and literature review on interface management of phamacotherapy

Chairs: Professor Carl-Gustaf Elinder and Ken Paterson

1.15-1.45 pm **Swedish and Stockholm healthcare including pharmaceuticals scenery**

Associate professor Rickard Malmström,
Karolinska Institutet and Karolinska University Hospital
Associate professor, pharmacist Björn Wettermark,
Stockholm County Council and Karolinska Institutet
(20 min presentation, 10 min discussion and comments)

1.45-2.35 pm **Presentation of Stockholm Model focusing on "Wise List"**

Lars L Gustafsson and Eva Andersén Karlsson
(40 min presentation, 10 min questions and discussions
relating to experiences across the globe)

2.35-2.40 pm **5 min break**

2.40-3.10 pm **Summary of literature review on interface management of pharmacotherapy (collaboration between primary and hospital care)**

Dr Sabine Vogler,
WHO Collaborating Centre for Pharmaceutical Pricing and
Reimbursement Policies, Austrian Health Institute

3.10-3.30 pm **Tea /Coffee break**

3.30-5.20 pm Hearing on the "Wise List": Panelists include DTC-members, officers and stake-holders

Chairs: Lars L Gustafsson/Senior researcher Brian Godman, Karolinska Institutet, Stockholm

Initial short presentations on key parts of the "Wise List" concept.

a. The "Wise List" – role of experts and critical medicine evaluation

(20 min presentation, 5 min questions)

- The key role of experts and opinion leaders
- Handling conflict of interest
- Medicine evaluation

Eva Andersén Karlsson

*Professor Paul Hjemdahl, Karolinska Institutet
Stockholm*

Rickard Malmström, Karolinska Institutet, Stockholm

b. The work process for selection of medicines in various editions of the "Wise List"

(15 min presentation, 5 min questions)

MD PhD Marie-Louise Ovesjö

c. Comprehensive communication of the "Wise List" recommendations including continuous medical education

(15 min presentation, 5 min questions)

Information officer Malena Jirlow and GPs Christer Norman and Jan Hasselström, Stockholm

40 min general discussion and 5 min for a summary of key points by participants.

5.20-5.45 pm Aims and planning of site visits on day 2

Chair: Pharmacist Kristina Johansson, Stockholm County Council

5.45 pm

Closure

Free evening

Day 2 – Wednesday, September 12

9.00 am–5.30 pm

Coordinator of site visits: Kristina Johansson

Startplace: Magnus Ladulåsgatan 63 A, at 9.00 am

IV: Site visits to practices, hospitals and institutions to study experience and application of the "Stockholm model"

Each group with 4 to 5 members will make two visits (one in the morning and one in the afternoon). Total 12 site visits. One officer guides at each visit

Visit 1: Morning – between 9.00 am to 1 pm (including lunch)

Transport maximum 1 hour

Visit 2: Afternoon – between 1.30 / 2 pm to 5.30 pm

Group A

Morning: *Unit for monitoring of medicine use and adherence.*

Host: Björn Wettermark et al

Afternoon: *The "Wise List" and the Stockholm Model at Karolinska University Hospital.*

Host: Associate professor, chief physician Johan Bratt

Group B

Morning: *Clinical pharmacology medicine evaluation group.*

Host: Rickard Malmström et al

Afternoon: *General practice visits.*

Host: Jan Hasselström et al, *Storvretens Practice Centre*

Group C

Morning: *Healthcare management board, Stockholm County Council.*

Host: Dr Henrik Almkvist

Afternoon: *General practice visits.*

Host: Dr Marianne Jägestedt et al, *Stureby Practice Centre*

Group D

Morning: *The "Wise List" and the Stockholm Model at St Göran, privately managed hospital.*

Host: Chief physician and chief pharmacist Peter Persson

Afternoon: *Unit for monitoring of medicine use and adherence.*

Host: Björn Wettermark et al.

Group E

Morning: *The "Wise List" and the Stockholm Model at Södersjukhuset.*

Host: Marie-Louise Ovesjö

Afternoon: *Clinical pharmacology services.*

Host: Professor and managing medical director Marja-Liisa Dahl

Group F

Morning: *The "Wise List" and pharmacies, Apoteket AB.*

Hosts: Lars-Åke Söderlund and Karin Söderberg

Afternoon: *"Wise List" and Stockholm Model at Danderyd Hospital.*

Host: Professor Thomas Kahan

7.00 pm

Invited dinner hosted by Stockholm Healthcare Region in collaboration with Karolinska Institutet

Day 3 – Thursday, September 13

9.00 am–5.30 pm

Coordinating chair: Eva Andersén Karlsson

9.00-10.30 am ***V: Site findings and way forward for Interface Management. Reports of findings at site visits with discussions***

Chairs: Eva Andersén Karlsson and Ken Paterson

Each of the six groups report key findings using one slide for 7 min followed by 2 min of discussion. Summing up with 30 min of general discussion and concluding remarks.

10.30-10.50 am **Tea/Coffee break**

10.50-11.20 am **Continued discussion of findings of site visits**

11.20am-2.00 pm **Group work on “Interface Management”**

Lunch included

Group work based on the “Wise List” and other models. Each group summarizes key suggestions on how to improve interface management to be discussed in plenary.

2.00–4.00 pm **Feedback of groups, discussions and conclusions**

Chairs: Eduardo Diogene and Eva Andersén Karlsson

Executive managers of healthcare, responsible politicians and researchers participate

4.00-4.45 pm **Main findings and future steps**

Richard Laing and Rickard Malmström

4.45-5.15 pm **Evaluation of course**

Eva Andersén Karlsson

*Pharmaceutical advisor Klara Tisocki, WHO Manila
Oyvind Melien*

5.15-5.30 pm **Final remarks**

Carl-Gustaf Elinder

7.00 pm **Informal dinner for people staying over**
(at their own expense)

Day 4 – Friday, September 14

Optional

In-depth discussions, consultations and site visits can be organized with participating and organizing experts related to Rational Use of Medicines, in particular hospital-primary care “interface management” in medicine therapy, and on the “Stockholm Model for Wise Use of Medicines”. The Swedish Drug Registration Body, Medical Products Agency, is in Uppsala close to Arlanda Airport. Karolinska Institutet is an internationally leading medical University with

strong research groups in several pharmacotherapeutic areas and with an internationally recognized centre for education and research in clinical pharmacology.

Organizing group, Stockholm

Chairperson DTC Stockholm, associate professor Eva Andersén Karlsson (chair), associate professor Johan Bratt, professor Carl-Gustaf Elinder, professor Lars L Gustafsson, communication officer Malena Jirlow, pharmacist Kristina Johansson, associate professor Rickard Malmström, executive secretary Paula Nordahl, executive secretary Anna-Lena Forssén, graphic designer Magnus Edlund.

International organizing group

Lars L Gustafsson Stockholm (chair), Dr Richard Laing, WHO Geneva, Eva Andersén Karlsson, Stockholm, Dr Brian Godman, Stockholm/Liverpool, Dr Oyvind Melien, Oslo, Dr Sabine Vogler, Vienna.

Welcome to Stockholm!